Vaccine & treatment
Ervebo (rVSV-ZEBOV-GP), approved 2019
Background
Zaire ebolavirus has a 70–90% fatality rate in untreated patients. The virus was first isolated in 1976 in Yambuku (DRC).
The approved Ervebo vaccine (single dose, ring vaccination) has been available since 2019 for this strain. Two approved monoclonal antibody treatments — Inmazeb (REGN-EB3) and Ebanga (mAb114) — dramatically reduce mortality when given early.